Compare Abeona Therapeutics Inc (ABEO) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Yum! Brands, Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Yum! Brands, Inc. trades at $150 (market cap $39.50B). The key difference: Yum! Brands, Inc. is far larger — about 93.8× Abeona Therapeutics Inc's market cap, and Yum! Brands, Inc. pays a 2.07% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | YUM | |
|---|---|---|
Market Cap | $421.19M | $39.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $168.16 |
52-Week Low | $4.17 | $138.21 |
Enterprise Value | $276.10M | $51.10B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
YUM trades at $150.15, up 3.32% in the past 24 hours, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings show a Q2 2026 beat with EPS of $1.62 versus $1.57 expected, while revenue grew to $8.21B in 2025. The company completed the sale of Pizza Hut China for $1.2B in August 2026, aiming to streamline operations and reduce debt. Cash flow from operations improved to $2.01B in 2025, supporting a dividend payment of $0.75 per share.
The outlook is mixed, with analyst consensus leaning hold (56.87%) but a price target of $174.60 implying 16% upside. Risks include ongoing legal investigations and a parasite outbreak impacting Taco Bell sales, though management reports recovery. Debt remains high at $11.25B long-term, but the debt-to-asset ratio improved to 143.49 in 2025. Execution on digital growth and brand focus post-Pizza Hut sale are key to unlocking value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
